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nother Look at
he Age-Old Question
hich Came First,
he Elevated C-Reactive Protein
r the Atherothrombosis?*
arc S. Sabatine, MD, MPH,
ugene Braunwald, MD, FACC
oston, Massachusetts
ultiple histologic studies of atheroma specimens have
llustrated the critical role of inflammation in the pathogen-
sis of atherosclerosis and plaque rupture (1). Proinflamma-
ory cytokines from T cells and macrophages recruit smooth
uscle cells and stimulate the production of interstitial
ollagens and proteoglycans, major components of the
xtracellular matrix that builds up in atheroma. Competing
ith plaque formation, however, is plaque degradation, a
rocess that also is driven by inflammation. Specifically,
hen macrophages accumulate at the shoulders of athero-
clerotic lesions and become activated, they release matrix
etalloproteinases that can weaken and eventually disrupt
he fibrous cap. This results in plaque rupture, intracoronary
hrombosis, and an acute coronary syndrome (ACS).
See page 238
There are several circulating biomarkers of inflammation,
ncluding cytokines such as interleukin (IL)-6, acute phase
eactants such as C-reactive protein (CRP), and leukocyte-
erived enzymes such as myeloperoxidase. Multiple clinical
tudies have demonstrated the association between elevated
evels of these inflammatory markers and the risk of myo-
ardial infarction (2–4). Yet it has been debated whether the
nflammatory state detected by these markers is a primary
rocess that predisposes to atherothrombosis or a conse-
uence of existing subclinical atherosclerosis.
In this issue of the Journal, Monaco et al. (5) present the
esults of an important study in which they compared the
therosclerotic burden and levels of thrombotic and inflam-
atory markers in patients with unstable angina (UA) to
hose in patients with peripheral arterial disease who were
dmitted for elective revascularization. They found that
atients with UA had fewer significant arterial stenoses and
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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erck.ower levels of thrombotic markers but much higher levels of
irculating inflammatory markers than patients with periph-
ral arterial disease. On the basis of this discordance, they
onclude that inflammation in ACS is unlikely to simply
eflect underlying atherosclerosis but, rather, represents a
rimary systemic process.
Given that the iliac and femoral arterial beds are more
xtensive than the coronary bed, it is not surprising that
eripheral angiography revealed more lesions than coronary
ngiography. To that end, it would have been helpful to
ave angiographic confirmation of the true atherosclerotic
urden in both vascular beds in both groups of patients. In
ddition, Liuzzo et al. (6) and Biasucci et al. (7) have
reviously shown that CRP and IL-6 levels are higher
uring the index admission in patients with UA than in
atients with stable angina (6,7). Moreover, serial studies in
atients with UA have demonstrated that CRP and IL-6
evels fall by approximately 50% in the following weeks (8).
hus, the observation in this study that inflammatory
arkers were nearly twice as high in patients with UA than
n patients with stable atherosclerosis, is not unexpected, but
oes underscore the marked difference between stable and
nstable atherothrombotic disease, irrespective of the in-
olved arterial bed.
In support of these observations, several large angio-
raphic studies have shown that no significant correlation
xists between the extent of coronary atherosclerosis and the
oncentration of circulating CRP (9,10). However,
ollow-up in these cohorts has demonstrated that an ele-
ated CRP predicts death or myocardial infarction indepen-
ent of the extent of baseline coronary artery disease. These
bservations emphasize that it tends to be the non–flow-
imiting, so-called “vulnerable” lipid-rich lesions with thin
brous caps and dense inflammatory cell infiltrates that are
he culprits in ACS (11).
Once patients present with ACS, there also is a direct
ontribution to the systemic inflammatory state from the
eart. CRP is generated in atherosclerotic plaques and has
een shown to be released into the coronary circulation in
atients with UA (12). In a series of experiments, Buffon et
l. (13) have shown previously that there is neutrophil
ctivation and myeloperoxidase release across the coronary
irculation in patients with UA but not in those with
hronic stable angina. Intriguingly, this activation was
bserved across coronary arteries regardless of whether they
ontained the culprit lesion. Whether this inflammation
riginates in the coronary vasculature or the myocardium
emains unclear (14).
What also is unclear is whether the widespread height-
ned cardiac inflammation is the culmination of an inflam-
atory process leading to plaque rupture, a consequence of
laque rupture, or both. Thus, akin to the ancient riddle of
hich came first, the chicken or the egg, the answer to the
uestion posed in the title of the editorial may be that CRP
omes both before and after atherothrombosis. Genetic
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January 18, 2005:244–5 Editorial Commentredisposition and environmental stimuli may lead to a
ore vigorous inflammatory state in certain individuals, a
tate detectable using CRP and other markers. Inflamma-
ion places patients with coronary plaques, even non-
bstructive ones, at higher risk for rupture and the conse-
uent development of ACS. The latter may then serve as an
dditional inflammatory stimulus, resulting in a further
ransient increase in CRP and other inflammatory markers.
y underscoring the disproportionate degree of inflamma-
ion in the setting of an ACS compared with extensive but
table arterial disease, the authors of this study help to
emind us of why anti-inflammatory therapy, currently by
tatins but hopefully soon by more potent agents, is critical
n preventing future cardiac ischemic events in patients
ithout known coronary disease (15), with stable coronary
isease (16), and with ACS (17).
Strong support for this position comes from a comparison
etween two recently published statin trials in patients with
CS. The Pravastatin or Atorvastatin Evaluation and
nfection Therapy: Thrombolysis In Myocardial Infarction
PROVE-IT TIMI)-22 trial compared standard lipid low-
ring with 40 mg of pravastatin to intensive lipid lowering
ith 80 mg of atorvastatin (18). The clinical benefit at 30
ays observed with the latter regimen was accompanied by
significantly lower CRP (19). In contrast, in the A to Z
rial, neither differences in clinical outcome nor in CRP
evels at 30 days were observed in patients assigned to 40 mg
f simvastatin versus placebo. Yet, later in the trial, when
he dose of simvastatin was raised to 80 mg/day, CRP was
educed and a clinical benefit emerged (20). Thus, in the
arly management of patients with ACS, it may not be
ufficient simply to lower the level of low-density lipopro-
ein cholesterol, as all three statins did in these trials; the
oal also must be to reduce inflammation, as reflected by
owering CRP.
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